DFTX trial shows DT120 100 mcg efficacy and safety in GAD
A phase III study reported that a single 100 microgram dose of DT120 produced rapid, robust, and durable efficacy with a favorable safety profile in GAD, outperforming placebo and the 50 microgram dose.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.